ACADIA Pharmaceuticals Inc.(Exact name of registrant as specified in its charter.)
Delaware
(State or other jurisdiction of incorporation or organization)
061376651
(IRS Employer Identification No.)
3611 Valley Centre Drive, Suite 300, San Diego, California 92130
(Address of principal executive offices)
858-558-2871
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
On February 18, 2016, Michael Borer notified us of his resignation as a member of our Board of Directors and the Audit Committee of the Board, effective immediately. In connection with Mr. Borer's resignation, Daniel Soland was appointed to the Audit Committee of the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ACADIA Pharmaceuticals Inc.
|
Date: February 24, 2016
| By: |
/s/ Glenn F. Baity |
|
| Name: Glenn F. Baity |
| Title: EVP, General Counsel & Secretary |